Differences between the different conditioning regimens for allogeneic stem cell transplantation

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 667-670

  Schattenberg, Anton V M B ^a   Levenga, Tjakiena H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Myeloablative stem cell transplantation; Non myeloablative stem cell transplantation; Reduced intensity stem cell transplantation; RIST

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC SYSTEM TUMOR; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

CLINICAL TRIALS AS TOPIC; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING;

EID: 33748882824     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245318.90015.72     Document Type: Review

References (12)

1. Baron F, Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 2006; 13:26-41. This is a very nice review article making a clear distinction between the different conditioning regimens.
2. Storb RF, Champlin R, Riddell SR, et al. Nonmyeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program 2001:375-391.
3. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49:511-533.
4. Ditschkowski M, Elmaagacli AH, Trenschel R, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin Transplant 2006; 20:127-131.
5. Schaap N, Schattenberg A, Bar B, et al. Induction of graft-versus- leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by preemptive donor leukocyte infusions. Leukemia 2001; 15:1339-1346.
6. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97:3390-3400.
7. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104:2254-2262.
8. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105:1810-1814.
9. Van Besien K, Carreras J, Zhang M-J, et al. Reduced intensity vs myeloablative conditioning for HLA matched sibling transplantation in follicular lymphoma [abstract]. Blood 2005; 106:656a.
10. Valcárcel D, Martino R, Sureda A, et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74:144-151.
11. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20:322-328.
12. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J, Bacigalupo A, Beelen D, Reiffers J, Devergie A, Alessandrino E, Mufti GJ, Barge R, Sierra J, Ruutu T, Boogaerts M, Falda M, Jouet JP, Niederwieser D, De Witte T. Retrospective comparison of reduced intensity conditioning and conventional high dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2006; 108:836-846. This very interesting study of the Chronic Leukaemia Working Party of the European Blood and Marrow Transplantation Group included a large cohort of patients with myelodysplastic syndromes. Illustrated with many clear tables and figures.